Apply This IPO

Best Margin

Zero Brokerage

24*7 Customer Support.

Fastest mobile support

---

Apply with Angel One

Apply with Zerodha

Pre-Apply with Upstox

Nephro Care India Limited IPO Review

Nephro care india private limited was started in 2014 by Dr. Pratim Sengupta in Kolkata to provide complete medical services for kidney patients. Today, Nephro Care is a one-stop center in Kolkata that offers various clinical and lifestyle solutions and treatments for patients with kidney problems.

Nephro Care India Limited's Ipo treatment approach includes all wellness aspects, such as lifestyle, physical health, and spiritual well-being. Nephro Care is run by a team of expert doctors, experienced paramedics, and a skilled management team, all backed by strong clinical and diagnostic facilities. Treatments at Nephro Care are based on solid scientific knowledge, honesty, and ethical practices. Their clinics have advanced equipment and diagnostic tools. They offer a wide range of diagnostic services, giving their doctors the ability to explore all possibilities and provide better care for their patients, all in one place, to ensure the best clinical results.

Nephro Care India Limited Products and Services

Nephro Care India Limited's goal is to help the million kidney disease patients across the country by combining modern medicine with proven yogic wisdom. They plan to achieve this using their hub-and-spoke model to reach as many people as possible.

Nephro Care India Limited Products and services are Bridging the gap between daycare and tertiary care services and addressing the unmet needs of the patient, Social Media Potheyred Community Engagement Model, Their technology backbone is robust and supports consistent improvements in the quality and efficiency of their service delivery, Hub-and-spoke’ model with focus on quality patient care supported by modern infrastructure, Focus on Clinical Research and Innovations, Professional Management & Experienced Leadership.

Financial Overview  

Nephro care india private limited ipo company provides healthcare services, including kidney insufficiency treatment. However, it has shown inconsistent net earnings in the reported periods. The sudden increase in profits for the first nine months of FY24 raises concerns about its future sustainability. Given its high annualized FY24 earnings, the investment seems overpriced. It might be wise to pass on this expensive option.